We are pleased to announce that IMA Group has acquired a majority shareholding in ProSys Group. ProSys will continue to operate independently with the same management team led by Michael McLoughlin, CEO.
For ProSys, this acquisition underscores the reputation the company has developed over the years for highly engineered quality solutions, particularly in key growth areas such as small-scale fill, cell & gene therapy, ADCs, HPAPI handling and peptides. It presents a tremendous opportunity to further expand our capabilities and market offering working with IMA Group who themselves are industry leaders in their varied fields of expertise.
For IMA Group, the acquisition further strengthens their proven competence in aseptic processing and containment solutions. It broadens their market offering in key target areas as referenced above and the combined entity will drive synergies and overall capability for the betterment of our end user client base.
For our existing and future clients, it remains business as usual; that is ‘to deliver on our commitments with a sense of urgency to exceed our customer expectations’.
We look forward to the future together.
